NASDAQ:CABA Cabaletta Bio (CABA) Stock Price, News & Analysis $5.56 -0.34 (-5.76%) (As of 10:29 AM ET) Add Compare Share Share Today's Range$5.52▼$5.9550-Day Range$4.01▼$12.5652-Week Range$3.47▼$26.35Volume124,840 shsAverage Volume1.14 million shsMarket Capitalization$268.42 millionP/E RatioN/ADividend YieldN/APrice Target$30.11 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Get Cabaletta Bio alerts: Email Address Cabaletta Bio MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside410.4% Upside$30.11 Price TargetShort InterestBearish18.17% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.73Based on 4 Articles This WeekInsider TradingN/AProj. Earnings GrowthDecreasingFrom ($2.07) to ($2.39) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.91 out of 5 starsMedical Sector637th out of 924 stocksBiological Products, Except Diagnostic Industry101st out of 145 stocks 4.5 Analyst's Opinion Consensus RatingCabaletta Bio has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 9 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageCabaletta Bio has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Cabaletta Bio's stock forecast and price target. Previous Next 1.0 Short Interest Percentage of Shares Shorted18.17% of the outstanding shares of Cabaletta Bio have been sold short.Short Interest Ratio / Days to CoverCabaletta Bio has a short interest ratio ("days to cover") of 7.1.Change versus previous monthShort interest in Cabaletta Bio has recently increased by 16.78%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldCabaletta Bio does not currently pay a dividend.Dividend GrowthCabaletta Bio does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for CABA. Previous Next 3.2 News and Social Media Coverage News SentimentCabaletta Bio has a news sentiment score of 0.73. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.44 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Cabaletta Bio this week, compared to 3 articles on an average week.Search InterestOnly 9 people have searched for CABA on MarketBeat in the last 30 days. This is a decrease of -10% compared to the previous 30 days.MarketBeat Follows7 people have added Cabaletta Bio to their MarketBeat watchlist in the last 30 days. This is an increase of 600% compared to the previous 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Cabaletta Bio insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 9.88% of the stock of Cabaletta Bio is held by insiders.Read more about Cabaletta Bio's insider trading history. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Cabaletta Bio are expected to decrease in the coming year, from ($2.07) to ($2.39) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Cabaletta Bio is -3.45, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Cabaletta Bio is -3.45, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCabaletta Bio has a P/B Ratio of 1.07. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Cabaletta Bio's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Insiders Exposed$5k to $1.3m in just 3 tradesIt doesn’t happen often, but occasionally, something completely unique comes across my radar. In this case, I’m talking about legal “Insider Trading”. Traders who have consistently signaled 453% … 610% .. and even 1036%... gains. And until now they have been doing it completely under the radar. In an upcoming interview I am revealing the strategy behind this gold-mine and how you can piggy back their every trade.Register for the imminent briefing here. About Cabaletta Bio Stock (NASDAQ:CABA)Cabaletta Bio, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases. The company's lead product candidate is CABA-201, a fully human anti-CD19 binder for the treatment of Phase 1/2 clinical trials in dermatomyositis, anti-synthetase syndrome, immune-mediated necrotizing myopathy, lupus nephritis, non-renal systemic lupus erythematosus, systemic sclerosis, and generalized myasthenia gravis. It also develops DSG3-CAART, which is in Phase I/II clinical trial for the treatment of mucosal pemphigus vulgaris; and MuSK-CAART, an investigational cell therapy that is in Phase I/II clinical trial for treating patients with anti- muscle-specific kinase antibody positive myasthenia gravis. It has a collaboration with the University of Pennsylvania and the Children's Hospital of Philadelphia; Nanjing IASO Biotherapeutics Co., Ltd; Oxford Biomedica; and WuXi Advanced Therapies, Inc. The company was formerly known as Tycho Therapeutics, Inc. and changed its name to Cabaletta Bio, Inc. in August 2018. Cabaletta Bio, Inc. was incorporated in 2017 and is headquartered in Philadelphia, Pennsylvania.Read More CABA Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart CABA Stock News HeadlinesAugust 21 at 9:40 AM | msn.comSeveral Headwinds Dragged Cabaletta Bio (CABA) in Q2August 20 at 3:13 PM | markets.businessinsider.comBuy Rating Affirmed for Cabaletta Bio Amid Superior CD19 CAR T Therapy Efficacy in Autoimmune Disease TreatmentAugust 22, 2024 | Insiders Exposed (Ad)$5k to $1.3m in just 3 tradesIt doesn’t happen often, but occasionally, something completely unique comes across my radar. In this case, I’m talking about legal “Insider Trading”. Traders who have consistently signaled 453% … 610% .. and even 1036%... gains. And until now they have been doing it completely under the radar. In an upcoming interview I am revealing the strategy behind this gold-mine and how you can piggy back their every trade.August 14, 2024 | americanbankingnews.comCabaletta Bio (NASDAQ:CABA) Price Target Cut to $20.00August 13, 2024 | uk.finance.yahoo.comRare Kidney Diseases Market Report 2024 to 2035, by Target Indications, Type of Molecule, Route of Administration and Key GeographiesAugust 13, 2024 | markets.businessinsider.comCabaletta Bio: Overweight Rating Maintained Amidst ICANS Incident and Adjusted Price TargetAugust 13, 2024 | americanbankingnews.comCabaletta Bio (NASDAQ:CABA) Given New $15.00 Price Target at Evercore ISIAugust 12, 2024 | americanbankingnews.comCabaletta Bio (NASDAQ:CABA) PT Lowered to $25.00 at HC WainwrightAugust 22, 2024 | Insiders Exposed (Ad)$5k to $1.3m in just 3 tradesIt doesn’t happen often, but occasionally, something completely unique comes across my radar. In this case, I’m talking about legal “Insider Trading”. Traders who have consistently signaled 453% … 610% .. and even 1036%... gains. And until now they have been doing it completely under the radar. In an upcoming interview I am revealing the strategy behind this gold-mine and how you can piggy back their every trade.August 10, 2024 | markets.businessinsider.comMaintaining Buy Recommendation on Cabaletta Bio Amid Overestimated Trial RisksAugust 10, 2024 | msn.comCabaletta Bio Reports Q2 2024 Financial Results and Provides Business UpdateAugust 8, 2024 | globenewswire.comCabaletta Bio Reports Second Quarter 2024 Financial Results and Provides Business UpdateJuly 25, 2024 | msn.comIASO Bio Announces NMPA Approval of IND Application for IASO-782 for Treatment of New Indication -- Systemic Lupus Erythematosus (SLE)July 8, 2024 | insidermonkey.comCabaletta Bio, Inc. (CABA): Why Are Analysts Loving This Shorted Stock Right Now?July 2, 2024 | globenewswire.comCabaletta Bio to Participate in the Stifel 2024 Virtual Cell Therapy ForumJune 14, 2024 | globenewswire.comCabaletta Bio Reports Positive Initial Clinical Data from Phase 1/2 RESET-Myositis™ and RESET-SLE™ Trials of CABA-201May 29, 2024 | finance.yahoo.comCabaletta Bio to Participate in the Jefferies Global Healthcare ConferenceMay 16, 2024 | msn.comCabaletta Bio Reports Promising Advances in Autoimmune Disease Trials, Looks to Future InnovationsSee More Headlines Receive CABA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Cabaletta Bio and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings8/08/2024Today8/22/2024Next Earnings (Estimated)11/14/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:CABA CUSIPN/A CIK1759138 Webwww.cabalettabio.com Phone267-759-3100FaxN/AEmployees50Year FoundedN/APrice Target and Rating Average Stock Price Target$30.11 High Stock Price Target$50.00 Low Stock Price Target$15.00 Potential Upside/Downside+410.4%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage9 Analysts Profitability EPS (Most Recent Fiscal Year)($1.71) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-67,680,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-38.77% Return on Assets-36.09% Debt Debt-to-Equity RatioN/A Current Ratio12.66 Quick Ratio12.66 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$5.51 per share Price / Book1.07Miscellaneous Outstanding Shares48,277,000Free Float43,507,000Market Cap$284.83 million OptionableOptionable Beta2.42 Ten Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free Report Key ExecutivesDr. Steven A. Nichtberger M.D. (Age 63)Co-Founder, Chairman, CEO & President Comp: $1.02MDr. Gwendolyn K. Binder Ph.D. (Age 49)President of Science & Technology Comp: $722.62kDr. David J. Chang FACR (Age 61)M.D., M.P.H., Chief Medical Officer Comp: $721.85kDr. Michael C. Milone M.D.Ph.D., Co-Founder & Co-Chair of Scientific Advisory BoardDr. Aimee Payne M.D.Ph.D., Co-Founder & Co-Chair of Scientific Advisory BoardMr. Anup Marda M.B.A. (Age 46)Chief Financial Officer Comp: $548.2kDr. Samik Basu M.D.Chief Scientific OfficerMr. Michael Gerard J.D. (Age 44)General Counsel & Secretary Ms. Heather Harte-Hall M.Sc.Chief Compliance OfficerMs. Martha O'ConnorChief Human Resources OfficerMore ExecutivesKey CompetitorsPraxis Precision MedicinesNASDAQ:PRAXEvolusNASDAQ:EOLSImmunomeNASDAQ:IMNMCronos GroupNASDAQ:CRON89bioNASDAQ:ETNBView All CompetitorsInsiders & InstitutionsPerceptive Advisors LLCSold 1,131,615 shares on 8/16/2024Ownership: 1.212%Millennium Management LLCBought 138,950 shares on 8/15/2024Ownership: 1.446%Deerfield Management Company L.P. Series CSold 794,398 shares on 8/15/2024Ownership: 0.962%AXA S.A.Bought 92,616 shares on 8/15/2024Ownership: 0.561%The Manufacturers Life Insurance Company Bought 4,191 shares on 8/15/2024Ownership: 0.117%View All Insider TransactionsView All Institutional Transactions CABA Stock Analysis - Frequently Asked Questions How have CABA shares performed this year? Cabaletta Bio's stock was trading at $22.70 on January 1st, 2024. Since then, CABA stock has decreased by 74.0% and is now trading at $5.90. View the best growth stocks for 2024 here. How were Cabaletta Bio's earnings last quarter? Cabaletta Bio, Inc. (NASDAQ:CABA) released its quarterly earnings results on Thursday, August, 8th. The company reported ($0.56) earnings per share for the quarter, missing the consensus estimate of ($0.55) by $0.01. When did Cabaletta Bio IPO? Cabaletta Bio (CABA) raised $87 million in an initial public offering (IPO) on Friday, October 25th 2019. The company issued 5,800,000 shares at a price of $14.00-$16.00 per share. Morgan Stanley, Cowen and Company and Evercore Group served as the underwriters for the IPO. Who are Cabaletta Bio's major shareholders? Cabaletta Bio's top institutional shareholders include Fred Alger Management LLC (5.23%), Sofinnova Investments Inc. (2.53%), Millennium Management LLC (1.45%) and Victory Capital Management Inc. (1.31%). Insiders that own company stock include Steven Nichtberger, Anup Marda, Gwendolyn Binder, Catherine Bollard and Ventures V LP 5Am. View institutional ownership trends. How do I buy shares of Cabaletta Bio? Shares of CABA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Cabaletta Bio own? Based on aggregate information from My MarketBeat watchlists, some other companies that Cabaletta Bio investors own include Alector (ALEC), Editas Medicine (EDIT), Kaleido Biosciences (KLDO), Sorrento Therapeutics (SRNE), Homology Medicines (FIXX), Skyworks Solutions (SWKS) and CrowdStrike (CRWD). This page (NASDAQ:CABA) was last updated on 8/22/2024 by MarketBeat.com Staff From Our PartnersAir Force quietly working with sub $10 stock on new techThere is a little-known energy technology stock that has made an incredible breakthrough… Which could becom...DTI | SponsoredTrump is sounding the alarmEurope is one of the latest to release a central bank digital currency and along with it, new cash rules. Chri...Preserve Gold | SponsoredThis Crypto Is Set to Explode in AugustWith the 2024 Bitcoin Halving, there's a potential HUGE bull run for altcoins. While everyone's chasing the...Crypto 101 Media | SponsoredUS developing “superweapon” to defeat China and Russia?Our new superweapon is a gift to every patriot. I predict the devastating new tech behind this weapon will cre...Paradigm Press | SponsoredSilver Grab of the Decade?In a groundbreaking move, J.P. Morgan now possesses the largest amount of physical silver in recorded history…...Colonial Metals | SponsoredAmazon coin set to soar 25X – starting August 19thChris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredAlex's "Next Magnificent Seven" StocksToday Alex Green is releasing his new breakdown of AI's "Next Magnificent Seven." So please make some time ...The Oxford Club | SponsoredThis One stock is all you need...What if you could ignore 99% of the stock market... And retire on just ONE ticker?Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cabaletta Bio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cabaletta Bio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
